Fulgent reports FID-007 + cetuximab Phase 2 HNSCC data: 60% ORR, 7.2 mo mPFS

Fulgent Genetics, Inc.

Interim Phase 2 data: ORR 60% (58% Arm A, 61% Arm B); mPFS 7.2 months across 42 evaluable patients.
Median DoR 7.4 months; 56% of responders still responding at Dec 20, 2025 cut-off; OS immature.
Favorable safety: mostly Grade 1-2 TRAEs; Grade 3-4 neutropenia, anemia, leukopenia; one Grade 5 pneumonia (Arm B).
Abstract #6020 presented at ASCO 2026 Rapid Oral Session on June 1, 2026 in Chicago.
Company notes historical standard-of-care offers ORR 5.8%-19.1% and PFS 2.3-3.7 months in R/M HNSCC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.